Alzheimer's Disease Treatment

Alzheimer's Disease Treatment

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alzheimer's Disease Treatment</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">[Lecanemab](/entities/lecanemab)</td>
<td>Aβ protofibrils</td>
</tr>
<tr>
<td class="label">[Donanemab](/entities/donanemab)</td>
<td>N-terminal Aβ</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Aβ plaques</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>Aβ plaques</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">[Cholinesterase inhibitors](/entities/cholinesterase-inhibitors)</td>
<td>[Donepezil](/entities/donepezil), [Rivastigmine](/entities/rivastigmine), Galantamine</td>
</tr>
<tr>
<td class="label">[NMDA receptor](/entities/nmda-receptor) antagonist</td>
<td>Memantine</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Namzaric</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector</td>
</tr>
<tr>
<td class="label">DNL311</td>
<td>Denali/Adimab</td>
</tr>
</table>

Alzheimer's Disease Treatment

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alzheimer's Disease Treatment</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Target</td>
</tr>
<tr>
<td class="label">[Lecanemab](/entities/lecanemab)</td>
<td>Aβ protofibrils</td>
</tr>
<tr>
<td class="label">[Donanemab](/entities/donanemab)</td>
<td>N-terminal Aβ</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Aβ plaques</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>Aβ plaques</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">[Cholinesterase inhibitors](/entities/cholinesterase-inhibitors)</td>
<td>[Donepezil](/entities/donepezil), [Rivastigmine](/entities/rivastigmine), Galantamine</td>
</tr>
<tr>
<td class="label">[NMDA receptor](/entities/nmda-receptor) antagonist</td>
<td>Memantine</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Namzaric</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>Alector/AbbVie</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>Alector</td>
</tr>
<tr>
<td class="label">DNL311</td>
<td>Denali/Adimab</td>
</tr>
</table>

Alzheimer's disease treatment encompasses pharmacological and non-pharmacological approaches aimed at modifying disease progression, managing symptoms, and improving quality of life. Current treatments include disease-modifying therapies targeting amyloid and [tau](/proteins/tau), symptomatic treatments for cognitive and behavioral symptoms, and lifestyle interventions[@masters2015][@cummings2024].

Disease-Modifying Therapies

Amyloid-Targeting Therapies

Monoclonal antibodies that remove [amyloid-beta](/proteins/amyloid-beta) plaques:

Tau-Targeting Therapies

Drugs targeting tau pathology:

• LMTM (Methylene Blue derivative): Tau aggregation inhibitor
• Anti-tau antibodies: Various in clinical development
• Tau kinase inhibitors: Target phosphorylation pathways

Other Mechanisms

• Synaptic plasticity enhancers: Ampakines
• Neuroprotective agents: Azeliragon
• Metabolic modulators: Type 2 diabetes drugs

Symptomatic Treatments

Cognitive Enhancers

Behavioral and Psychological Symptoms

• Antidepressants: SSRIs for depression and anxiety
• Antipsychotics: Risperidone, olanzapine (cautious use)
• Prazosin: For agitation
• Brexpiprazole: For agitation in AD

Non-Pharmacological Interventions

Cognitive Stimulation

• Cognitive training: Computerized brain training
• Reminiscence therapy: Using memories to improve mood
• Reality orientation: Time and place reinforcement

Lifestyle Modifications

• Physical exercise: Regular aerobic activity
• Social engagement: Maintaining relationships
• Sleep hygiene: Managing sleep disturbances
• Diet: Mediterranean diet, MIND diet

Caregiver Support

• Education programs: Understanding disease progression
• Support groups: Emotional support
• Respite care: Caregiver relief

Emerging Treatments

In Development

Prevention Trials

• A4 study: Anti-amyloid treatment in preclinical AD
• DIAN-TU: Genetic forms of AD
• Generation studies: [APOE](/proteins/apoe)-targeted prevention

TREM2 Agonists and Microglial Activation

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a cell surface receptor primarily expressed on microglia in the brain. It plays a critical role in modulating microglial function, including phagocytosis, metabolic reprogramming, survival signaling, and clustering around pathological protein deposits. Loss-of-function variants in TREM2 (such as R47H, R62H) significantly increase Alzheimer's disease risk, making TREM2 activation a promising therapeutic strategy[@jonsson][@wang].

Mechanism of Action

TREM2 agonists work by:

• Enhancing phagocytosis: Activating microglia to clear amyloid-beta plaques and cellular debris more efficiently
• Supporting disease-associated microglia (DAM): Promoting the inflammatory metabolic state of protective microglial phenotypes
• Providing survival signals: Preventing microglial apoptosis and maintaining cell viability
• Promoting plaque clustering: Facilitating microglial clustering around amyloid plaques to form protective barriers

Clinical Trials

AL002 (Alector/AbbVie)

AL002 is a monoclonal antibody designed to activate TREM2 by binding to a distinct epitope that promotes receptor clustering and signaling. It represents the first TREM2-targeting antibody to enter clinical trials for Alzheimer's disease.

• Phase 1 (completed): Demonstrated dose-dependent engagement of TREM2 and acceptable safety profile in healthy volunteers and AD patients
• Phase 2 (INVOKE-2, ongoing): Evaluating clinical efficacy in patients with early Alzheimer's disease
• Enrollment: Approximately 265 participants with early AD
• Primary endpoints: Change in amyloid PET, cognitive measures (ADAS-Cog13, ADCS-ADL), and multiple fluid and imaging biomarkers
• Mechanism: Intended to optimize TREM2 signaling to improve microglia activity and counteract decreased TREM2 functionality

AL003 (Alector)

AL003 uses a different mechanism, potentially acting as a TREM2-activating antibody with enhanced brain penetration.

• Status: Phase 1 completed, clinical development continued with strategic partner

Pipeline Summary

Eligibility Criteria

Patients being considered for TREM2 agonist trials typically meet the following criteria:

• Age: Typically 50-85 years
• Diagnosis: Mild cognitive impairment (MCI) due to AD or mild Alzheimer's disease
• Amyloid status: Confirmed amyloid-positive via PET scan or CSF biomarkers
• MMSE score: Usually 20-26 (mild disease)
• Exclusion: No significant vascular disease, psychiatric conditions, or other neurodegenerative diseases

Safety and Adverse Effects

Similar to other antibody therapies targeting immune pathways:

• ARIA-E: Amyloid-related imaging abnormalities - edema; monitoring required via MRI
• ARIA-H: Microhemorrhages; particular attention in anti-amyloid combination trials
• Infusion reactions: Potential for cytokine release with first doses
• Infections: Monitor for respiratory and urinary tract infections
• Long-term immune modulation: Effects on microglial function require extended monitoring

Biomarkers for Patient Selection

• CSF sTREM2: Soluble TREM2 in cerebrospinal fluid reflects microglial activation and may predict treatment response
• Genetic stratification: Patients with TREM2 risk variants (R47H, R62H) may particularly benefit from TREM2 agonism
• Amyloid status: Required for patient selection as amyloid plaques are the primary ligand for microglial phagocytosis

Treatment Guidelines

Clinical Practice Recommendations

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Donepezil](/therapeutics/donepezil)
• [Lecanemab](/therapeutics/lecanemab)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Donepezil](/therapeutics/donepezil)
• [Lecanemab](/therapeutics/lecanemab)
• [TREM2 Agonists](/therapeutics/trem2-agonists)
• [Microglial Modulation Therapies](/therapeutics/microglial-modulation-therapies)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PVALB
• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
• [GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GFAP
• [Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: SLC17A7
• [SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction](/hypothesis/h-seaad-v4-5a7a4079) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: SIRT3

• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) &#x1f504;
• [Protein aggregation cross-seeding across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-9137255b) &#x1f504;
• [Mechanistic role of APOE in neurodegeneration](/analysis/SDA-2026-04-01-gap-auto-fd6b1635d9) &#x1f504;